Key regions: Japan, India, Italy, Brazil, South Korea
Suriname, a small country located in South America, has a developing market for Anti-Hypertensive Drugs.
Customer preferences: The customers in Suriname prefer generic drugs over branded ones due to their cost-effectiveness. This preference is not unique to Suriname, as generic drugs are gaining popularity worldwide due to their affordability. Another customer preference in Suriname is for drugs with minimal side effects. Customers prefer drugs that do not cause any adverse effects, and this is a trend that is seen worldwide.
Trends in the market: The Anti-Hypertensive Drugs market in Suriname is expected to grow due to the increasing prevalence of hypertension in the country. Hypertension is a common health problem in Suriname, and it is estimated that more than one-third of the adult population suffers from it. This trend is not unique to Suriname, as hypertension is a growing problem worldwide. The market for Anti-Hypertensive Drugs is also expected to grow due to the increasing awareness of the importance of hypertension management.
Local special circumstances: Suriname is a small country with a population of just over 600,000 people. The healthcare system in Suriname is still developing, and there is a shortage of healthcare professionals. This shortage can lead to delays in the diagnosis and treatment of hypertension, which can have a significant impact on the market for Anti-Hypertensive Drugs. The lack of healthcare professionals can also lead to a lack of awareness about hypertension and its management.
Underlying macroeconomic factors: The economy of Suriname is heavily dependent on the export of natural resources, particularly gold and oil. The country has experienced economic difficulties in recent years due to a decline in commodity prices. This economic downturn can have an impact on the market for Anti-Hypertensive Drugs. Customers may be less likely to purchase drugs due to financial constraints, and the government may have less money to invest in the healthcare system. However, the government has taken steps to improve the healthcare system in Suriname, which could have a positive impact on the market for Anti-Hypertensive Drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
